Prolonged reduction of high blood pressure with an in vivo, nonpathogenic, adeno-associated viral vector delivery of AT1-R mRNA antisense

M. Ian Phillips, Dagmara Mohuczy-Dominiak, Mark Coffey, Sara M. Galli, Birgitta Kimura, Ping Wu, Tibor Zelles

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

To produce a prolonged decrease in blood pressure, we have developed a nonpathogenic adeno-associated viral vector (AAV) with the antisense DNA for AT1-R. AAV has many advantages over other viral vectors. AAV does not stimulate inflammation or immune reaction. AAV enters nondividing cells and does not replicate. Therefore, it is an appropriate choice for gene therapy. Recombinant AAV was prepared with a cassette containing a cytomegalovirus promoter and the cDNA for the AT1 receptor inserted in the antisense direction. The cassette was packaged in the virion. Stable transfection of NG108-15 cells with the pAAV-AS (plasmid AAV) antisense to AT1-R produced a significant reduction in AT1 receptors. A single injection of the rAAV-AS (viral vector) was made in adult spontaneously hypertensive rats, either directly in the hypothalamus (1 μL) or in the lateral ventricles (5 μL). The result shows that there is a significant decrease of blood pressure (≃23±2 mm Hg) for up to 9 weeks after injection. Control injections of mock vector produced no change in blood pressure during the same time period in age-matched controls. In young spontaneously hypertensive rats (3 weeks), a single intracardiac injection of recombinant rAAV-AS reduced blood pressure and slowed the development of hypertension compared with controls (P<.01). The results suggest that a prolonged reduction in high blood pressure can be achieved with AAV vectors delivering antisense to inhibit AT1 receptors with a single administration.

Original languageEnglish (US)
Pages (from-to)374-380
Number of pages7
JournalHypertension
Volume29
Issue number1 II
StatePublished - Jan 1997
Externally publishedYes

Fingerprint

Blood Pressure
Hypertension
Messenger RNA
Injections
Inbred SHR Rats
Antisense DNA
Lateral Ventricles
Cytomegalovirus
Genetic Therapy
Virion
Hypothalamus
Transfection
Plasmids
Complementary DNA
Inflammation
Direction compound

Keywords

  • angiotensin
  • antisense
  • AT receptor
  • hypertension
  • NG108-15 cells
  • recombinant adeno-associated virus (AAV) vector

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Phillips, M. I., Mohuczy-Dominiak, D., Coffey, M., Galli, S. M., Kimura, B., Wu, P., & Zelles, T. (1997). Prolonged reduction of high blood pressure with an in vivo, nonpathogenic, adeno-associated viral vector delivery of AT1-R mRNA antisense. Hypertension, 29(1 II), 374-380.

Prolonged reduction of high blood pressure with an in vivo, nonpathogenic, adeno-associated viral vector delivery of AT1-R mRNA antisense. / Phillips, M. Ian; Mohuczy-Dominiak, Dagmara; Coffey, Mark; Galli, Sara M.; Kimura, Birgitta; Wu, Ping; Zelles, Tibor.

In: Hypertension, Vol. 29, No. 1 II, 01.1997, p. 374-380.

Research output: Contribution to journalArticle

Phillips, MI, Mohuczy-Dominiak, D, Coffey, M, Galli, SM, Kimura, B, Wu, P & Zelles, T 1997, 'Prolonged reduction of high blood pressure with an in vivo, nonpathogenic, adeno-associated viral vector delivery of AT1-R mRNA antisense', Hypertension, vol. 29, no. 1 II, pp. 374-380.
Phillips, M. Ian ; Mohuczy-Dominiak, Dagmara ; Coffey, Mark ; Galli, Sara M. ; Kimura, Birgitta ; Wu, Ping ; Zelles, Tibor. / Prolonged reduction of high blood pressure with an in vivo, nonpathogenic, adeno-associated viral vector delivery of AT1-R mRNA antisense. In: Hypertension. 1997 ; Vol. 29, No. 1 II. pp. 374-380.
@article{1abe635a0fcd4a4d91b897aaf31aaad4,
title = "Prolonged reduction of high blood pressure with an in vivo, nonpathogenic, adeno-associated viral vector delivery of AT1-R mRNA antisense",
abstract = "To produce a prolonged decrease in blood pressure, we have developed a nonpathogenic adeno-associated viral vector (AAV) with the antisense DNA for AT1-R. AAV has many advantages over other viral vectors. AAV does not stimulate inflammation or immune reaction. AAV enters nondividing cells and does not replicate. Therefore, it is an appropriate choice for gene therapy. Recombinant AAV was prepared with a cassette containing a cytomegalovirus promoter and the cDNA for the AT1 receptor inserted in the antisense direction. The cassette was packaged in the virion. Stable transfection of NG108-15 cells with the pAAV-AS (plasmid AAV) antisense to AT1-R produced a significant reduction in AT1 receptors. A single injection of the rAAV-AS (viral vector) was made in adult spontaneously hypertensive rats, either directly in the hypothalamus (1 μL) or in the lateral ventricles (5 μL). The result shows that there is a significant decrease of blood pressure (≃23±2 mm Hg) for up to 9 weeks after injection. Control injections of mock vector produced no change in blood pressure during the same time period in age-matched controls. In young spontaneously hypertensive rats (3 weeks), a single intracardiac injection of recombinant rAAV-AS reduced blood pressure and slowed the development of hypertension compared with controls (P<.01). The results suggest that a prolonged reduction in high blood pressure can be achieved with AAV vectors delivering antisense to inhibit AT1 receptors with a single administration.",
keywords = "angiotensin, antisense, AT receptor, hypertension, NG108-15 cells, recombinant adeno-associated virus (AAV) vector",
author = "Phillips, {M. Ian} and Dagmara Mohuczy-Dominiak and Mark Coffey and Galli, {Sara M.} and Birgitta Kimura and Ping Wu and Tibor Zelles",
year = "1997",
month = "1",
language = "English (US)",
volume = "29",
pages = "374--380",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "1 II",

}

TY - JOUR

T1 - Prolonged reduction of high blood pressure with an in vivo, nonpathogenic, adeno-associated viral vector delivery of AT1-R mRNA antisense

AU - Phillips, M. Ian

AU - Mohuczy-Dominiak, Dagmara

AU - Coffey, Mark

AU - Galli, Sara M.

AU - Kimura, Birgitta

AU - Wu, Ping

AU - Zelles, Tibor

PY - 1997/1

Y1 - 1997/1

N2 - To produce a prolonged decrease in blood pressure, we have developed a nonpathogenic adeno-associated viral vector (AAV) with the antisense DNA for AT1-R. AAV has many advantages over other viral vectors. AAV does not stimulate inflammation or immune reaction. AAV enters nondividing cells and does not replicate. Therefore, it is an appropriate choice for gene therapy. Recombinant AAV was prepared with a cassette containing a cytomegalovirus promoter and the cDNA for the AT1 receptor inserted in the antisense direction. The cassette was packaged in the virion. Stable transfection of NG108-15 cells with the pAAV-AS (plasmid AAV) antisense to AT1-R produced a significant reduction in AT1 receptors. A single injection of the rAAV-AS (viral vector) was made in adult spontaneously hypertensive rats, either directly in the hypothalamus (1 μL) or in the lateral ventricles (5 μL). The result shows that there is a significant decrease of blood pressure (≃23±2 mm Hg) for up to 9 weeks after injection. Control injections of mock vector produced no change in blood pressure during the same time period in age-matched controls. In young spontaneously hypertensive rats (3 weeks), a single intracardiac injection of recombinant rAAV-AS reduced blood pressure and slowed the development of hypertension compared with controls (P<.01). The results suggest that a prolonged reduction in high blood pressure can be achieved with AAV vectors delivering antisense to inhibit AT1 receptors with a single administration.

AB - To produce a prolonged decrease in blood pressure, we have developed a nonpathogenic adeno-associated viral vector (AAV) with the antisense DNA for AT1-R. AAV has many advantages over other viral vectors. AAV does not stimulate inflammation or immune reaction. AAV enters nondividing cells and does not replicate. Therefore, it is an appropriate choice for gene therapy. Recombinant AAV was prepared with a cassette containing a cytomegalovirus promoter and the cDNA for the AT1 receptor inserted in the antisense direction. The cassette was packaged in the virion. Stable transfection of NG108-15 cells with the pAAV-AS (plasmid AAV) antisense to AT1-R produced a significant reduction in AT1 receptors. A single injection of the rAAV-AS (viral vector) was made in adult spontaneously hypertensive rats, either directly in the hypothalamus (1 μL) or in the lateral ventricles (5 μL). The result shows that there is a significant decrease of blood pressure (≃23±2 mm Hg) for up to 9 weeks after injection. Control injections of mock vector produced no change in blood pressure during the same time period in age-matched controls. In young spontaneously hypertensive rats (3 weeks), a single intracardiac injection of recombinant rAAV-AS reduced blood pressure and slowed the development of hypertension compared with controls (P<.01). The results suggest that a prolonged reduction in high blood pressure can be achieved with AAV vectors delivering antisense to inhibit AT1 receptors with a single administration.

KW - angiotensin

KW - antisense

KW - AT receptor

KW - hypertension

KW - NG108-15 cells

KW - recombinant adeno-associated virus (AAV) vector

UR - http://www.scopus.com/inward/record.url?scp=0031027401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031027401&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 374

EP - 380

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 1 II

ER -